PFE Stock DD Pfizer, Inc. 11/04/2014 10:03:55

Message Board

Previous

| Next

Post# of 250666

Posted On: 11/04/2014 11:03:50 AM

Posted By: Rosner

PFE Pfizer, Inc. $PFE Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=PFE&...mp;yt0=Go!

Last Updated: 11/04/2014 10:03:51

Current Price and Quotes
Last Price 29.98
Previous Close 30.19 Open 30.14
Daily Range 29.96 - 30.30 52wk Range 27.51 - 32.96
Volume 6,034,077 Dividend 1.04
Average Vol (30d) 28,070,558 Yield 3.469

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 51,584,000 54,657,000 61,035,000 65,165,000
Cost of Revenue 9,586,000 9,821,000 12,500,000 14,788,000
Gross Profit 41,998,000 44,836,000 48,535,000 50,377,000
Operating Expenses

Research and Development 6,678,000 7,482,000 8,681,000 9,483,000
Sales, General and Admin. 14,355,000 15,171,000 17,581,000 18,973,000
Non-Recurring Items 1,182,000 1,810,000 2,841,000 3,145,000
Other 4,599,000 5,109,000 5,465,000 5,364,000
Operating Income 15,184,000 15,264,000 13,967,000 13,412,000
Income From Continuing Operations

Add'l Income/Expense Items 532,000 (4,022,000) (2,486,000) (3,941,000)
Earnings Before Interest and Tax 15,716,000 11,242,000 11,481,000 9,471,000
Interest Expense - - - -
Earnings Before Tax 15,716,000 11,242,000 11,481,000 9,471,000
Income Tax 4,306,000 2,221,000 3,621,000 1,153,000
Minority Interest 69,000 28,000 40,000 31,000
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 11,410,000 9,021,000 7,860,000 8,318,000
Non Recurring Events

Discontinued Operations 10,662,000 5,577,000 2,189,000 (30,000)
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 22,003,000 14,570,000 10,009,000 8,257,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 22,003,000 14,570,000 10,009,000 8,257,000

Recent News
Source
Nov 4, 2014 Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix PR NEWSWIRE
Nov 4, 2014 "Goodbye Mr. Jones": The End Of The Dow As An American Index Seeking Alpha
Nov 3, 2014 7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides Seeking Alpha
Oct 30, 2014 How Cash-Rich Companies Might Repatriate Foreign Profits Tax-Free, Liberating The Nation From Political Gridlock At The Same Time Seeking Alpha
Oct 29, 2014 Pfizer Receives FDA Accelerated Approval for TRUMENBA(R) (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults BUSINESS WIRE
Oct 29, 2014 How Did High-Yield Dividend Champions Do During The Great Recession? Part 2 Seeking Alpha
Oct 29, 2014 Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly PR NEWSWIRE
Oct 29, 2014 Pfizer's PRISTIQ(R) (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder BUSINESS WIRE
Oct 29, 2014 Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success Seeking Alpha
Oct 28, 2014 Pfizer's (PFE) CEO Ian Read on Q3 2014 Results - Earnings Call Transcript Seeking Alpha

1
2
3
4
5
6
7
8
next >
last >>

(0)

(0)